Verona Pharma (VRNA) 10-Q2022 Q1 Quarterly report

Filed: 3 May 22, 8:24am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: Additionally, anniversary, annum, AstraZeneca, AUC, background, baseline, bona, Brady, career, Chief, clarify, collateral, collateralize, Court, covenant, customary, default, Director, discount, discovery, discretion, disposition, division, drop, earliest, earn, endpoint, English, entry, essentially, expiratory, extensive, failure, fee, feedback, fide, final, floating, GCP, High, history, HM, HMRC, iii, imposed, improvement, indemnification, industry, insufficient, introduced, IP, Journal, leadership, letter, lien, mature, maturity, MedImmune, meet, minimum, modification, monthly, national, NIC, outsourced, PAYE, penalty, pledge, population, post, predominantly, prepay, prime, prohibited, rate, reimbursement, release, repayment, Russia, SGRQ, SME, smoking, Street, subordinated, SVB, Ukraine, unpaid, validate, vendor, volume, Wall, week

Removed: arise, attributable, cashlessly, contractually, discussed, domestic, effect, efficacy, exercised, exposed, facilitating, fall, February, finance, forfeited, higher, international, intrinsic, investing, involving, issuer, lower, method, model, narrow, objective, parameter, patient, present, purpose, referred, satisfied, shorter, sterling, structured, traded, unconsolidated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VRNA transcripts

VRNA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verona Pharma plc (the “Company”) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 3, 2022	By:	/s/ David Zaccardelli, Pharm.D.
		David Zaccardelli, Pharm.D.
		Chief Executive Officer (principal executive officer)